Related Experiment Videos
Erythromycin as a prokinetic agent: risk factors
S Berthet1, B Charpiat, J Y Mabrut
1Service de pharmacie, hôpital de la Croix-Rousse, 103 Grande Rue de la Croix-Rousse, Lyon cedex 04, France.
Journal of Visceral Surgery
|July 27, 2010
Summary
Erythromycin improves gastric emptying but carries risks like drug interactions and cardiac events. Careful benefit-risk assessment and clear communication are crucial for safe prescription.
Area of Science:
- Pharmacology
- Gastroenterology
- Clinical Therapeutics
Background:
- Erythromycin (ER) is an antibiotic with prokinetic properties used for gastroparesis.
- Its effectiveness in improving gastric emptying is debated due to methodologically flawed studies.
- Contradictory results highlight the need for a thorough benefit-risk analysis.
Purpose of the Study:
- To provide new insights into the adverse events associated with Erythromycin.
- To enable more informed prescription decisions regarding Erythromycin use.
- To emphasize the importance of understanding ER's risks and benefits.
Main Methods:
- Review of existing literature on Erythromycin's efficacy and safety.
- Analysis of reported adverse events, including drug interactions and cardiovascular complications.
- Focus on methodological quality of previous studies.
Main Results:
- Erythromycin's prokinetic effects are supported by some evidence, but clinical outcomes are often inconsistent.
- Significant risks include numerous medication interactions and serious cardiovascular events like torsade de pointes and cardiac arrest.
- Methodological limitations in prior studies impact the reliability of reported efficacy.
Conclusions:
- A comprehensive benefit-risk assessment is essential before prescribing Erythromycin.
- Preventing cardiovascular complications and managing drug interactions are critical.
- Effective communication among healthcare professionals (surgeons, anesthesiologists, pharmacists) is vital for risk mitigation.
Related Concept Videos
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...